Advertisement

Advertisement

ADVERTISEMENT

Videos

IRd vs Placebo-Rd for Patients With Newly-Diagnosed MM

Videos

IRd vs Placebo-Rd for Patients With Newly-Diagnosed MM

12/20/2020

12/20/2020

Journal of Clinical Pathways

HCRU, Costs With CAR-T Therapy Compared to Transplantation for DLBCL

Videos

HCRU, Costs With CAR-T Therapy Compared to Transplantation for DLBCL

12/17/2020

Karl Kilgore, PhD, discusses study results that showed greater HCRU and costs with CAR-T therapy than transplantation for patients with relapsed/refractory DLBCL.

Karl Kilgore, PhD, discusses study results that showed greater HCRU and costs with CAR-T therapy than transplantation for patients with relapsed/refractory DLBCL.

Karl Kilgore, PhD, discusses...

12/17/2020

Journal of Clinical Pathways

Real-World Biomarker Testing, Treatment Patterns in CLL/SLL

Videos

Real-World Biomarker Testing, Treatment Patterns in CLL/SLL

12/17/2020

Anthony Mato, MD, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with CLL in the clinical practice setting, using the informCLL prospective registry.

Anthony Mato, MD, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with CLL in the clinical practice setting, using the informCLL prospective registry.

Anthony Mato, MD, discusses...

12/17/2020

Journal of Clinical Pathways

First-Line Ibrutinib Demonstrates Long-Term Efficacy in TP53-Mutated CLL

Videos

First-Line Ibrutinib Demonstrates Long-Term Efficacy in TP53-Mutated CLL

12/16/2020

12/16/2020

Journal of Clinical Pathways

$Real-World Comparison of DRd and DPd for Relapsed/Refractory MM$

Videos

Real-World Comparison of DRd and DPd for Relapsed/Refractory MM

12/09/2020

Muhamad Alhaj Moustafa, MD, presents findings from a study comparing daratumumab plus lenalidomide and dexamethasone (DRd) vs daratumumab plus pomalidomide and dexamethasone (DPd) for lenalidomide-exposed patients with relapsed or refractory...

Muhamad Alhaj Moustafa, MD, presents findings from a study comparing daratumumab plus lenalidomide and dexamethasone (DRd) vs daratumumab plus pomalidomide and dexamethasone (DPd) for lenalidomide-exposed patients with relapsed or refractory...

Muhamad Alhaj Moustafa, MD,...

12/09/2020

Journal of Clinical Pathways

Real-World Comparison of Costs, Outcomes of LBCL With or Without Transplantation

Videos

Real-World Comparison of Costs, Outcomes of LBCL With or Without Transplantation

12/09/2020

12/09/2020

Journal of Clinical Pathways

HCRU and Costs Associated With CAR-T Therapy Toxicity Management in MM

Videos

HCRU and Costs Associated With CAR-T Therapy Toxicity Management in MM

12/08/2020

12/08/2020

Journal of Clinical Pathways

Daratumumab Plus RVd Continues to Demonstrate Improved Responses in MM

Videos

Daratumumab Plus RVd Continues to Demonstrate Improved Responses in MM

12/07/2020

12/07/2020

Journal of Clinical Pathways

Daratumumab Plus VCd Improves Responses in Newly Diagnosed AL Amyloidosis

Videos

Daratumumab Plus VCd Improves Responses in Newly Diagnosed AL Amyloidosis

12/07/2020

12/07/2020

Journal of Clinical Pathways

$Belantamab Mafodotin Plus Bortezomib and Dexamethasone for Relapsed/Refractory MM$

Videos

Belantamab Mafodotin Plus Bortezomib and Dexamethasone for Relapsed/Refractory MM

12/04/2020

12/04/2020

Journal of Clinical Pathways

Specialties

Prostate Cancer

JCP May/June 2024 Issue

Current Issue

June 2024

Volume 10

Issue 3

More Content

Blogs

Popular Articles

Conference Coverage

Use of Homologous Recombination Thresholds for Forecasting Response to Platinum-Based Treatment in Triple-Negative Breast Cancer

06/14/2022

Ellen Kurek

Ellen Kurek

Researchers at ASCO conducted an exploratory analysis evaluating the ability of GIS thresholds of 33 or greater, and 42 or greater to predict response to platinum-based treatment in patients with triple-negative breast cancer.

Researchers at ASCO conducted an exploratory analysis evaluating the ability of GIS thresholds of 33 or greater, and 42 or greater to predict response to platinum-based treatment in patients with triple-negative breast cancer.

Researchers at ASCO conducted an...

06/14/2022

Journal of Clinical Pathways

Shlomit Amar-Farkash, PhD, MSc

Videos

Real-World Study Compares Third and Subsequent Line Regimens for Treating Metastatic Triple-Negative Breast Cancer

07/14/2022

Shlomit Amar-Farkash, PhD, MSc, compared the impact of treatment with Eribulin vs other commonly used chemotherapies as third and subsequent lines of therapy on overall survival and post-treatment hospitalizations among patients with...

Shlomit Amar-Farkash, PhD, MSc, compared the impact of treatment with Eribulin vs other commonly used chemotherapies as third and subsequent lines of therapy on overall survival and post-treatment hospitalizations among patients with...

Shlomit Amar-Farkash, PhD, MSc,...

07/14/2022

Journal of Clinical Pathways

News

Trends in Medicare Utilization and Reimbursement for Spinal Cord Stimulators

08/17/2022

Yvette C Terrie

Yvette C Terrie

The number of percutaneous and open procedures as well as reimbursement per procedure have progressively expanded from 2000 to 2019, according to a recent study.

The number of percutaneous and open procedures as well as reimbursement per procedure have progressively expanded from 2000 to 2019, according to a recent study.

The number of percutaneous and...

08/17/2022

Journal of Clinical Pathways

News

Score Model for Prediction and Prognosis of Patients With Advanced NSCLC Treated With Nivolumab or Pembrolizumab

09/27/2022

Yvette C Terrie

Yvette C Terrie

Findings from a study provide further validation of Patras Immunotherapy Score among patients with advanced non-small-cell lung cancer treated with anti-programmed-cell death 1 monotherapy.

Findings from a study provide further validation of Patras Immunotherapy Score among patients with advanced non-small-cell lung cancer treated with anti-programmed-cell death 1 monotherapy.

Findings from a study provide...

09/27/2022

Journal of Clinical Pathways

Sayeh Lavasani, MD, MS, FRCPC

Videos

Utilizing Pathways to Mitigate Costs in Metastatic Breast Cancer Treatment

10/16/2022

Sayeh Lavasani, MD, MS, FRCPC, highlights the financial advantage of pathways, stating that clinical pathway utilization can save up to 35% in the cost of treatment in breast cancer, while providing up-to-date, evidence-based treatment...

Sayeh Lavasani, MD, MS, FRCPC, highlights the financial advantage of pathways, stating that clinical pathway utilization can save up to 35% in the cost of treatment in breast cancer, while providing up-to-date, evidence-based treatment...

Sayeh Lavasani, MD, MS, FRCPC,...

10/16/2022

Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement